Latest Neurochemistry Stories
It’s been another landmark year for cannabinoids and the cannabinoid system, with new breakthrough research and additional confirmations of their importance to a healthy human race. Here's a list of the Top Ten 2012 Cannabinoid Stories according to Publius – the pen name used by the authors of The Cannabis Papers: A Citizen’s Guide to Cannabinoids (2011). Chicago, IL (PRWEB) December 31, 2012 It’s been another landmark year for cannabinoids and the cannabinoid system, with new...
Law Implements Real-Time, Stop-Sale Technology WASHINGTON, Dec. 21, 2012 /PRNewswire-USNewswire/ -- The Consumer Healthcare Products Association (CHPA) today applauded Ohio Governor John Kasich for signing into law House Bill 334, an anti-methamphetamine bill authored by Representative Terry Johnson (R-Portsmouth) and Representative Danny Bupb (R-West Union). With the new law, Ohio now becomes the 25th state to adopt real-time, stop-sale technology known as the National Precursor Log...
MIAMI, Dec. 20, 2012 /PRNewswire/ -- Consumers won't find Elite Serum on the shelves at Sephora or Ulta, next to the ho-hum anti-aging eye cream products that make various and often unsubstantiated claims about their ability to reduce the symptoms of age. SkinPro, the fastest growing cosmeceutical company in the world, prefers distribution through medical centers and spas staffed with licensed estheticians. The reason SkinPro prefers this type of product distribution is due to the...
NEW YORK, Dec. 18, 2012 /PRNewswire/ -- An annual Harris Poll that measures the percentage of Americans perceiving 19 large industries as "generally honest and trustworthy" finds that the most trusted industries are supermarkets and hospitals, followed distantly by online search engines, computer software companies, banks, computer hardware companies and electric and gas utilities. The poll also finds that industries which the largest percentages of U.S. adults would like to see...
ALISO VIEJO, Calif., Dec. 12, 2012 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today reported financial results for the three and twelve months ended September 30, 2012. Quarterly Financial Highlights Gross and net NUEDEXTA® sales of $15.4 million and $12.4 million, respectively, an increase of 26% and 23% versus the previous quarter Total company net revenue of $13.5 million Cash, cash equivalents, and restricted investments of $72.1 million as of September 30,...
LONDON, December 12, 2012 /PRNewswire/ -- Announces up to 25% OFF this Christmas on SteamLite Electronic Cigarette Website to say Thank You! To say thank you to loyal long-term customers Steamlite have introduced 25% off on all orders placed during this month. Steamlite has always been known for its quality products at affordable prices amongst buyers. Steamlite kits are sold nearly half the price of some other giants in the industry with none or little difference in...
SUNNYVALE, Calif., Nov. 29, 2012 /PRNewswire/ -- Amarantus Bioscience, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced that an independent peer-reviewed research paper entitled Upregulation of mesencephalic astrocyte-derived neurotrophic factor in glial cells is associated with ischemia-induced glial...
ALISO VIEJO, Calif., Nov. 27, 2012 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced preliminary results for the quarter ended September 30, 2012. Financial Update Based on preliminary results for the fourth fiscal quarter ended September 30, 2012, Avanir estimates: Gross revenue for NUEDEXTA® of $15.4 million, representing an increase of approximately 26% over the prior quarter Total operating expenses, excluding cost of product sales and non-cash...
SUNNYVALE, Calif., Nov. 27, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new disease-modifying treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced that the Company has successfully completed experiments demonstrating that MANF has an excellent diffusion profile in the striatum of rat brains. The striatum is located in the...
POINT RICHMOND, Calif., Nov. 26, 2012 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) announced today that Purdue Pharmaceutical Products, L.P. (Purdue), the Transcept U.S. commercialization partner for Intermezzo® (zolpidem tartrate) sublingual tablet C-IV, is launching a national direct-to-consumer (DTC) promotional campaign, including digital, print and television advertising to support Intermezzo commercialization. Intermezzo digital and print DTC campaigns began...
